Remove 2025 Remove Innovation Remove Peripheral Arterial Disease
article thumbnail

Johnson and Johnson Completes Acquisition of Shockwave Medical

DAIC

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. in 2024 and approximately $0.17

article thumbnail

Johnson and Johnson to Acquire Shockwave Medical

DAIC

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD). in 2024 and approximately $0.17